Blog - Uhthoff

Regulatory Certainty Strategy for Biosimilar Drugs in Mexico

Mexico has been continuously facing the new challenges related to the growing biotechnology industry. Mexican authorities have recognized that the current regulation does not generate the ideal conditions to allow the effective entry (from the clinical phase to obtaining marketing authorizations) of new innovative treatments, biosimilars or interchangeable generics. Since November 2021, Mexico was accepted […]